Drugs / CardiALLO™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05925608 | Aug 2023 → Dec 2026 expected | systolic heart failure | BioCardia, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-04-15 | BioCardia, Inc. | Results BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial biocardia.com ↗
There have been no treatment emergent major adverse cardiac events observed nor has there been any clinical evidence of immune reactions to the allogeneic cells implanted. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CardiALLO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05925608 ↗ |
| Modality | Cell therapy | “The CardiALLO cell therapy is an allogenic bone marrow-derived cell treatment” NCT05925608 ↗ |